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Abstract
Background & Aims—Impairment of sleep quality is common in patients with inflammatory
bowel diseases (IBD; Crohn’s disease [CD], ulcerative colitis [UC]), even during clinical
remission. Sleep impairment can activate inflammatory pathways. Few prospective studies have
examined the role of sleep disturbance on risk of relapse in IBD.
Methods—We analyzed data from 3173 patients with IBD (1798 in clinical remission at
baseline) participating in the Crohn’s and Colitis Foundation of America Partners study, a
longitudinal, internet-based cohort. Sleep disturbance was measured using a subset of questions
from the Patient Reported Outcomes Measurement Information Systems sleep disturbance
questionnaire. Disease activity was assessed using the short Crohn’s disease activity index and
simple clinical colitis activity index for CD and UC respectively. Logistic regression was used to
identify predictors of sleep quality and examine the effect of sleep quality at baseline among
patients in remission on risk of active disease at 6 months.
Results—Disease activity, depression, female gender, smoking, and use of corticosteroids or
narcotics were associated with sleep disturbance at enrollment. Among 1291 patients whose CD
was in remission at baseline, those with impaired sleep had 2-fold increase in risk of active disease
at 6 months (adjusted odds ratio [OR], 2.00; 95% confidence interval [CI], 1.45–2.76); no effect
was observed in patients with UC (OR 1.14; 95% CI 0.75 – 1.74). These findings persisted in a
number of sensitivity analyses.
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Conclusion—Sleep disturbance was associated with an increased risk of disease flares in CD but
not UC. These findings indicate that the evaluation and treatment of sleep disturbance in patients
with CD might improve outcomes.
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INTRODUCTION
Inflammatory bowel diseases (IBD; Crohn’s disease (CD), ulcerative colitis (UC)) are
chronic immunologically mediated diseases of the intestine that often have their onset
during young adulthood and are characterized by a chronic relapsing and remitting
course1, 2. They are associated with considerable morbidity, need for surgery and
hospitalizations, and impairment of health-related quality of life3, 4. However, despite our
understanding that external environment, behavior, and lifestyle play an important role in
the pathogenesis and natural history of CD and UC5–8, such factors remain poorly studied.
In particular, there has been little study of behavioral factors other than smoking that might
influence disease activity, but that could also be modifiable and reduce the risk of active
disease.
Sleep disturbances are common in the population and associated with a spectrum of adverse
outcomes including being a risk factor for obesity, weight gain, metabolic syndrome,
depression, and mortality9–11. Prior studies support the biological plausibility that disturbed
sleep may be a modifiable behavioral risk factor for disease relapse in IBD patients12–17.
Patients with IBD, even during period of inactivity, have a higher prevalence of impaired
sleep quality than healthy controls14. In animal models, acute or chronic sleep deprivation
increases susceptibility to dextran sodium sulfate (DSS)-induced colitis, a widely used
mouse model of IBD18. Key cytokines involved in chronic inflammation including tumor
necrosis factor-α (TNF), interleukin-1 (IL-1), and interleukin-6 (IL-6) affect sleep17. In
human studies of juvenile idiopathic arthritis, administration of anti-TNF biologic therapy
improves sleep quality in addition to the achieving disease remission19. There have been no
prior studies examining the association between sleep quality in remission and risk of
subsequent disease flare in patients with established CD or UC.
In the context of a large prospective IBD cohort, we performed this study with the following
aims: (1) to identify predictors of sleep quality among patients with CD and UC; and (2) to
examine if sleep quality during remission is associated with subsequent risk of symptomatic
flares in patients with CD and UC.
METHODS
Study Cohort and variables
The data source for this study was the Crohn’s and Colitis Foundation of America (CCFA)
Partners IBD cohort. The creation of this cohort has been described in detail in previous
publications20, 21. In brief, CCFA Partners is a longitudinal internet-based cohort of patients
with IBD. Participants with a self-reported diagnosis of UC, CD, or indeterminate colitis
(IC) who were older than age 18 years were invited to participate in the study through the
CCFA email roster, social media, and at educational events21. All participants completed a
baseline survey comprising demographics and information about their IBD. Optional
modules on various patient-reported outcomes were included with the baseline survey. They
were then invited to complete a follow-up questionnaire at 6 months after enrollment,
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ascertaining disease activity as well as any changes in their treatment and repeated measures
of patient-reported outcomes.
Assessment of sleep disturbance
Our main predictor variable of interest was sleep disturbance. This was ascertained using a
subset of questions from the National Institutes of Health Patient Reported Outcomes
Measurement Information Systems (PROMIS) sleep disturbance questionnaire22, 23. The
PROMIS sleep disturbance questionnaire was carefully developed within the PROMIS
domain framework by first creating an initial pool of items identified from 535 candidate
citations. Focus-groups were then held among those with sleep disorders and normal
sleepers, and the question bank pilot tested in a national sample of 300 participants and a
clinical sample. Subsequent psychometric testing using classic test theory and item response
theory analyses were used to arrive at the final questionnaire which demonstrated excellent
measurement properties. The short form of the PROMIS questionnaire has comparable
performance to the widely used Pittsburgh Sleep Quality Index (PSQI) and greater ability to
discriminate between different levels of sleep disturbance23, 24. Furthermore, the response
burden to the PROMIS sleep questions is lower than for the 10-item PSQI, does not require
participation of a sleeping partner, and is consistent with ascertainment of other patient-
reported outcome measures in this cohort. In addition, each PROMIS question from the 29-
item bank is designed as a stand alone question with the same final score irrespective of the
number of questions completed25.
For this study, patients were administered four questions that examined sleep quality.
Respondents were asked if over the past 7 days, (1) their sleep quality was good, (ii) their
sleep was refreshing, (iii) they had a problem with their sleep, or (iv) they had difficulty
falling asleep. Responses were scored on a 5-point Likert scale. The sum of the responses
was normalized to a T-score with mean of 50 and a standard deviation (SD) of 10
(www.nihpromis.org). Thus, a T-score of 50 refers to the median sleep quality with higher
scores indicating a greater degree of sleep disturbance. Patients with a sleep T-score > 50
were considered as having disturbed sleep while T-scores < 50 were considered normal. In
sensitivity analyses, we defined disturbed sleep as requiring a T-score > 60, and as a
continuous variable. To validate our use of the PROMIS questions, a subset of patients were
also administered the PSQI. Correlation between the two questionnaires was examined using
the Pearson correlation co-efficient.
Other Variables
Self-reported disease location and behavior in CD and extent of involvement in UC was
classified according to the Montreal classification26. Information was obtained about IBD-
related hospitalization or surgery, as well as medications for treatment of IBD including 5-
aminosalicylates (oral), corticosteroids (oral), immunomodulators, and biologic therapies
(infliximab, adalimumab, certolizumab pegol, and natalizumab). Disease activity was
assessed using validated measures - the short Crohn’s disease activity index (SCDAI) for
CD27 and the simple clinical colitis activity index (SCCAI) for UC28. A SCDAI < 150 or an
SCCAI ≤ 2 indicated clinical remission for CD and UC respectively with values above this
threshold indicating active disease21. Baseline depressive symptoms were ascertained using
a PROMIS depression T-score scored similar to the sleep T-score. Medication adherence
was assessed using the Morisky Medication Adherence Scale (MMAS)29. Smoking status
was stratified as never, past, and current smoking at the time of baseline questionnaire with
very few (< 10 patients) describing a change in their smoking status at 6 months.
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Our primary outcome was presence of active disease at 6 months. This was defined as
SCDAI > 150 for CD or SCCAI > 2 for UC on the 6-month follow-up questionnaire. As a
secondary outcome, we assessed an expanded definition of disease flare which included
either a disease activity index above the threshold above, or initiation of a new IBD
medication, requirement for an IBD-related surgery or hospitalization between the baseline
and follow-up visit. In the validation study, patient and physician reports matched 98% of
the time for ever having bowel surgery, and current pouch or ostomy status. In a sensitivity
analysis, we used an alternate definition of active disease that included an SCDAI > 150 and
a 100-point increase in SCDAI from baseline for CD and an SCCAI > 5 for UC.
Statistical Analysis
All analysis was performed using Stata 11.0 (StataCorp, College Station, TX). Continuous
variables were summarized using means and standard deviations and compared using the t-
test. Categorical variables, expressed as proportions, were compared using the chi-square
test. Univariate and multivariable logistic regression models were constructed to identify
predictors of disturbed sleep at cohort entry. This analysis included the entire cohort of
3,173 patients. Next, among participants who were in clinical remission at baseline
(n=1,798), we evaluated the association between sleep disturbance during remission and risk
of disease flare. Variables significant in the univariate analyses at p-value < 0.10 were
included in the final multivariable regression models where a p-value < 0.05 indicated
independent statistical significance. The study was approved by the Institutional Review
Board (IRB) of Massachusetts General Hospital. The CCFA Partners cohort study was
approved by the IRB of University of North Carolina, Chapel Hill.
RESULTS
Study Cohort
A total of 4,366 individuals who had both a baseline and a 6-month follow-up survey were
eligible for inclusion in our study. The median interval between completion of the baseline
and follow-up survey was 7 months (interquartile range (IQR) 6.5 – 7.8 months). After
excluding patients with a stoma or pouch (as standard symptom-based measures of disease
activity are not applicable to these patients), indeterminate colitis, a change in their IBD
diagnosis during the follow-up period, and those with missing data on sleep disturbance or
disease activity scores, we arrived at the final cohort of 3,173 patients (Figure 1). A total of
1,798 patients (507 UC, 1291 CD) were in clinical remission at baseline. Patients excluded
from the study were similar to the final cohort in age and gender, were slightly more likely
to have UC, and had a lower frequency of prior hospitalization or surgery.
Validation of assessment of sleep disturbance
A total of 773 patients completing the 6-month follow-up questionnaire completed both the
PSQI and the PROMIS sleep T. Overall, there was a strong correlation between the two
scores (correlation co-efficient 0.80, p < 0.0001). The correlation remained good for patients
with active disease or in remission, and by IBD type. The mean PSQI for those without or
with sleep impairment by the PROMIS sleep-T scores was 4 and 9 respectively (p < 0.0001).
Four-fifths (82%) of patients with sleep-T scores above the median and 98% of those with
sleep-T scores above 60 had a PSQI > 5.
Predictors of sleep disturbance at baseline
Nearly two-thirds of patients (60%) in the study had sleep disturbance at baseline. Such
patients were more likely to be female, have CD, or have a history of smoking (p < 0.05 for
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all) (Table 1). They were also more likely to be currently using systemic corticosteroids,
narcotics, or anti-TNF biologic therapies, and were more likely to have ever required an
IBD-related hospitalization or surgery. Over half the patients with sleep disturbance had
active disease (55%) compared to a quarter of those with no sleep disturbance (26%) (p <
0.001). Conversely, 48% of those in remission at baseline had sleep T-scores > 50 compared
to 76% of those with active disease (p < 0.001). On multivariable analysis, the strongest
predictors of disturbed sleep were depressive symptoms (Odds ratio (OR) 2.75, 95%
confidence interval (CI) 2.34 – 3.23) and the presence of active disease (OR 2.61, 95% CI
2.19 – 3.11), while female gender, diagnosis of CD, and both past and current smoking
conferred modest risks (Table 2). Current use of corticosteroids and narcotics, but not anti-
TNF biologics or immunomodulators also independently increased risk of sleep disturbance.
Sleep disturbance and risk of disease flare in Crohn’s disease
Half of the 1,291 patients with CD in remission at baseline had disturbed sleep (n = 651,
50%). Participants with sleep disturbance while in clinical remission were more likely to be
women, have CD or have a history of smoking. Neither corticosteroids nor narcotic use were
associated with disturbed sleep in this cohort likely owing to their low frequency of use
among those in remission (Table 3). Among those with disturbed sleep, 22% of those in
remission had active disease at month 6 compared to 12% of those without disturbed sleep
(OR 1.96, 95% CI 1.45 – 2.65). On multivariable analysis, presence of sleep disturbance
was associated with twofold increase in risk of disease flare at 6 months (OR 2.00, 95% CI
1.45 – 2.76) (Table 4). Using the expanded definition of disease flare incorporating either
active symptoms or initiation of new therapies, we found a similar effect of sleep
disturbance on disease flare (OR 1.64, 95% CI 1.27 – 2.11). Defining disease flare as
requiring both a SCDAI > 150 and a 100-point increase in the score from baseline also
yielded a similar effect size (OR 1.70, 95% CI 1.09 – 2.65). To explore the possibility of
subclinical symptoms at baseline below our remission threshold influencing sleep status and
likelihood of flare, in a sensitivity analysis we defined remission as SCDAI ≤ 200, and
active disease on follow-up as values above this threshold. The association with sleep
impairment and subsequent active disease was further strengthened on this analysis (OR
1.95, 95% CI 1.37 – 2.79). Participants who had no impaired sleep at baseline but sleep
impairment on follow-up and follow-up surveys were significantly more likely to have
active disease at the follow-up (OR 2.37, 95%I CI 1.46 – 3.86) than those whose sleep
remained unimpaired. Adjusting for baseline body mass index did not influence our results.
Similar results were found after adjusting for medication adherence using the MMAS (data
available on 832 patients) (OR 1.63, 95% CI 1.10 – 2.42) or depressive symptoms (data
available on 1206 patients) (OR 1.77, 95% CI 1.27 – 2.45). On a continuous scale, each 10
point (1 standard deviation) increase in the PROMIS sleep T-score was associated with a
50% increase in risk of disease flare (OR 1.46, 95% CI 1.19 – 1.79) (Table 5). Patients with
the greatest disturbance in sleep quality (PROMIS T-score > 60) had an OR of 2.21 (95% CI
1.30 – 3.77) compared to those with T-scores of 50 or less (Table 5). We did not find a
statistically significant interaction by age, gender, disease phenotype, depressive symptoms,
or medication adherence in susceptibility to the effect of sleep disturbance (p > 0.05 for all
interactions).
Sleep disturbance and risk of disease flare in ulcerative colitis
In contrast to its effect on CD, we observed no effect between sleep disturbance at baseline
and risk of disease flare in UC using either our primary (OR 1.14, 95% CI 0.75 – 1.74) or
expanded definitions of disease flare (OR 1.14, 95% CI 0.75 – 1.74) (Table 4).
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Sleep impairment is common in chronic inflammatory diseases13–17, 30–37. Biologic
mechanisms support a potential role for sleep impairment in disease relapse in IBD15–17;
nevertheless there are no published studies examining this hypothesis. Using a large IBD
cohort, we demonstrate that CD patients who have impaired sleep quality while in clinical
remission have a greater risk of disease flare. We did not identify this effect in UC.
There has been limited research on sleep disturbances in patients with IBD. Ranjbaran et al.
administered the PSQI to 205 patients with IBD, IBS or healthy controls and found that
patients with IBD, despite being in remission, had significantly prolonged sleep latency,
sleep fragmentation, decreased daytime energy and poor overall sleep quality compared to
healthy controls15. Sleep quality was associated with lower health-related quality of life
(HRQoL)15. However the assessment of sleep quality and HRQoL was cross-sectional (i.e.
at the same time point). A larger study of 318 patients with CD and UC demonstrated that
77% of those with active and 49% of those with inactive disease experienced poor sleep
measured using the PSQI33. This is nearly identical to our proportion of 76% and 48% of
those with active disease or in remission using the PROMIS sleep questions.
Impairment of sleep in patients with IBD is likely multifactorial. During periods of active
disease, the need for nocturnal bowel movements as well as persistence of symptoms such as
abdominal pain can result in sleep disturbance. Second, medications frequently used in the
setting of active disease such as corticosteroids or narcotics may result in impaired sleep.
Third, associated psychiatric co-morbidities including depression and anxiety more common
in IBD patients38 also influence sleep quality. However, we found that nearly half the
patients in clinical remission also had impaired sleep quality. One hypothesis for this
occurrence is the presence of subclinical inflammation in such patients. Injection of IL-1 or
TNF-α in animal models suppresses rapid-eye movement (REM) sleep and alters sleep
patterns39. Administration of IL-6 increases non-rapid eye movement sleep (NREM) and
reduces slow wave sleep during the first half of the sleep cycle40. Thus, elevated circulating
cytokines in patients in clinical remission could contribute to the sleep disturbances.
A key and novel finding of our study is that CD patients who had disturbed sleep even while
in clinical remission had nearly two-fold increase in likelihood of disease flare at 6 months
compared to those with unimpaired sleep. Considerable laboratory evidence supports the
biologic plausibility of such an association. Sleep deprivation in humans is associated with
an increase in IL-6 and TNF soluble receptors16, 17, 37. In an elegant study, Tang et al.
examined the effect of sleep deprivation on susceptibility to DSS-induced colitis18. Three
groups of twelve mice each were subjected to acute sleep deprivation (24 hours), chronic
intermittent sleep deprivation (10 days), and no deprivation. Both the acute and chronically
sleep deprived mice displayed increased susceptibility to DSS colitis and exacerbation of
colon inflammation18. Additionally, TNF-α can influence expression of clock genes which
are involved in regulating intestinal permeability17, 41. Finally, sleep disturbance is
associated with activation of natural killer cells and monocytes17, 37, 41. There is less direct
evidence for why we observed an effect on CD but not UC. This is unlikely to be related to
statistical power given similar number of patients with CD or UC in our study, similar rates
of active disease, and widely used measures of disease activity. Thus, it is possible that sleep
quality as an environmental variable truly does not impact the course of ulcerative colitis.
While the vast number of genetic risk loci for CD and UC are shared, distinct dominant
pathways exist in the pathogenesis of each disease7. Our findings add to the literature
demonstrating differential effect of various environmental factors on CD and UC –
classically smoking and appendectomy. The mechanisms for this divergence in effect for
any of the parameters described remained yet undefined. Identifying such divergence in
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effects provides strong impetus to understanding the mechanisms how the environment may
influence different components of the immune system, and may help further our
understanding of the pathogenesis of these diseases.
There are several implications to our findings. The association between sleep impairment
and disease relapse suggests a need to incorporate assessment of sleep quality more
routinely in our care of patients with IBD. Identification of sleep disturbances could
potentially yield a modifiable risk factor to reduce the likelihood of subsequent disease
relapse. There is need for research on the effectiveness of interventions to improve sleep
quality. Also, given the identified association between corticosteroid and narcotic use and
sleep quality, it is important for the treating physician to recognize these iatrogenic causes of
sleep impairment, potentially modify treatment regimens, or institute interventions to
address these treatment-related adverse effects. As well, identification of an association
between depressive symptoms and sleep quality suggests the need to also continue to
incorporate routine screening for psychiatric co-morbidity in the management of patients
with IBD.
We acknowledge several limitations to our study. First, the CCFA Partners cohort is a
volunteer sample of patients. It is possible that the IBD patients enrolled in CCFA Partners
may differ from a population-based IBD cohort. Nevertheless, the prevalence of sleep
disturbance stratified by disease activity at baseline in our cohort is similar to that identified
in the Manitoba population-based IBD cohort, suggesting our results may be generalizable
to the larger IBD population. Second, diagnosis of IBD was by self-report. However,
according to preliminary results from a validation study in which the treating physicians of
randomly selected members of the cohort were mailed a 10-item questionnaire to confirm
IBD type and diagnosis, IBD status was confirmed in 96% of the cohort, with matching IBD
type confirmed 94% of the time (data not shown). Third, information on disease phenotype,
treatment, and disease activity was by self-report. The bias introduced due to this is unlikely
to be differential by sleep impairment. The use of symptom-based disease activity scores is
also subject to limitations including influence by superimposed irritable bowel syndrome.
However, we attempted to increase the robustness of our results by demonstrating
consistency of effect using an alternate definition that relied not just on symptom-based
indices but also more objective measures including initiation of new IBD treatments, surgery
or hospitalizations. We also did not have information on whether patients were on sleep aids
at the time of assessment. However, this misclassification is also likely to bias towards the
null, making our results a conservative estimate. Both sleep quality and disease activity was
assessed for the 1 week period prior to completion of the questionnaire, allowing for these to
be more representative measures that 24-hour recall. As in all observational studies, the
possibility of unmeasured confounders exists. We attempted to adjust for most of the known
important environmental factors, but were not able to fully capture all possibilities including
use of over the counter medications. Finally, we examined outcomes up to 6 months after
assessment of sleep quality. It is important to continue studies of environmental, behavioral,
and lifestyle factors beyond this time frame to identify the long-term impact of such
variables.
In conclusion, we identified sleep impairment during remission to be a risk factor for disease
flares in CD in a large IBD cohort. Continued research is needed to further understand the
mechanisms behind such an association. Furthermore, our findings suggest that sleep quality
could be a modifiable factor in reducing risk of disease relapses in IBD. There is need for
further research on the potential benefits of routine assessment of sleep quality as well as
intervention–based studies to improve sleep quality in patients with CD which may
ultimately impact patient outcomes.
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Figure 1. Flow chart establishing study cohort
PROMIS – NIH Patient Reported Outcomes Measurement Information Systems
IBD – Inflammatory bowel disease
SCDAI – short Crohn’s disease activity index, SCCAI – simple clinical colitis activity index
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Table 1
Baseline characteristics of the study cohort
No sleep disturbance (n = 1,267) % Disturbed sleep (n = 1,906) % p-value
Median age in years (IQR) 43 (31 – 57) 45 (32 – 56) 0.90
Median age at diagnosis (IQR) 26 (20 – 39) 27 (20 – 39) 0.94
Female 70 75 0.005
IBD type 0.003
 Crohn’s disease 62 68
 Ulcerative colitis 38 32
Smoking status < 0.001
 Never 68 61
 Past 28 32
 Current 4 7
Family history of IBD 24 22 0.06
Depressive symptoms‡ 33 63 < 0.001
Current medication use
 Steroids 10 17 < 0.001
 5-aminosalicylates 52 49 0.10
 Immunomodulators 32 30 0.41
 Anti-TNF biologics 31 34 0.04
 Narcotics 4 11 < 0.001
Prior IBD surgery 30 35 0.005
Prior hospitalization 59 63 0.01
Crohn’s Phenotype 0.05
 Inflammatory 42 37
 Stricturing 38 39
 Penetrating 19 23
Crohn’s Location 0.004
 Ileal 34 30
 Colonic 17 13
 Ileocolonic 47 56
 Upper GI only 2 1
Perianal Crohn’s 26 30 0.09
UC Extent 0.65
 Proctitis 5 5
 Left-sided colitis 43 42
 Pancolitis 37 40
 Unavailable 15 13
Active disease† 26 55 < 0.001
IBD – Inflammatory bowel disease; CD – Crohn’s disease; UC – ulcerative colitis; IQR – interquartile range
‡
 Depressive symptoms were defined as having a PROMIS depression T-score > 50
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†
 Active disease was defined as SCCAI > 2 for patients with UC and a SCDAI > 150 for patients with CD
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Table 2
Predictors of disturbed sleep|| at baseline in the full cohort (n = 3,173)
Parameter Odds Ratio 95% confidence interval
Sex
 Male Reference
 Female 1.18 0.99 – 1.41
IBD type
 Crohn’s disease Reference
 Ulcerative colitis 0.74 0.61 – 0.90
Smoking status
 Never Reference
 Past 1.28 1.09 – 1.50
 Current 2.17 1.55 – 3.03
Steroid use
 No Reference
 Yes 1.33 1.04 – 1.70
Anti-TNF use
 No Reference
 Yes 1.03 0.87 – 1.23
Narcotics
 No Reference
 Yes 1.65 1.17 – 2.35
Prior IBD hospitalization
 No Reference
 Yes 1.06 0.88 – 1.28
Prior IBD surgery
 No Reference
 Yes 0.87 0.71 – 1.07
Active disease†
 No Reference
 Yes 2.61 2.19 – 3.11
Depressive symptoms‡
 No Reference
 Yes 2.75 2.34 – 3.23
||
Disturbed sleep was defined as having a PROMIS sleep T-score > 50
‡
 Depressive symptoms were defined as having a PROMIS depression T-score > 50
†
 Active disease was defined as SCCAI > 2 for patients with UC and a SCDAI > 150 for patients with CD
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Table 3
Characteristics of the cohort of patients in remission at baseline, stratified by sleep disturbance||
No sleep disturbance (n = 932) % Disturbed sleep (n = 857) % p-value
Age 45 (16) 45 (15) 0.67
Age at diagnosis 30 (14) 30 (13) 0.80
Female 69 74 0.04
IBD type 0.001
 CD 68 75
 UC 32 25
Smoking status 0.015
 Never 70 64
 Past 26 31
 Current 4 5
Family history of IBD 24 24 0.96
Depressive symptoms‡ 27 50 < 0.001
Current medication use
 Steroids 7 9 0.10
 5-aminosalicylates 51 49 0.59
 Immunomodulators 32 30 0.27
 Anti-TNF therapy 32 33 0.64
 Narcotics 3 5 0.06
Prior IBD surgery 68 63 0.06
Prior hospitalization 40 38 0.34
Crohn’s Phenotype 0.11
 Inflammatory 42 41
 Stricturing 39 36
 Penetrating 19 24
Crohn’s Location 0.16
 Ileal 36 34
 Colonic 17 13
 Ileocolonic 46 52
 Upper GI only 1.6 1.4
Perianal Crohn’s 26 28 0.61
UC Extent 0.33
 Proctitis 5 4
 Left-sided colitis 38 45
 Pancolitis 40 38
 Unavailable 16 12
IBD – Inflammatory bowel disease; CD – Crohn’s disease; UC – ulcerative colitis; SD – standard deviation
||
Disturbed sleep was defined as having a PROMIS sleep T-score > 50
‡
 Depressive symptoms were defined as having a PROMIS depression T-score > 50
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